Veradermics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Equivalents	21.77	53.08	16.3
Short-Term Investments	120.1	-	-
Cash & Short-Term Investments	141.86	53.08	16.3
Cash Growth	167.24%	225.75%	-
Other Receivables	1.26	1.38	-
Receivables	1.26	1.38	-
Prepaid Expenses	5.61	1.04	1.22
Other Current Assets	3.77	0.04	0.05
Total Current Assets	152.49	55.54	17.56
Property, Plant & Equipment	0.13	-	-
Total Assets	152.62	55.54	17.56
Accounts Payable	2.13	2.25	1.85
Accrued Expenses	6.98	2.47	1.2
Other Current Liabilities	0.05	-	-
Total Current Liabilities	9.15	4.72	3.05
Long-Term Debt	-	-	0.79
Long-Term Leases	0	-	-
Total Liabilities	9.16	4.72	3.84
Common Stock	0	0	0
Additional Paid-In Capital	2.35	0.75	0.5
Retained Earnings	-123.42	-49.23	-22.74
Comprehensive Income & Other	-1.79	-3.85	-0.89
Total Common Equity	-122.86	-52.33	-23.14
Shareholders' Equity	143.46	50.82	13.72
Total Liabilities & Equity	152.62	55.54	17.56
Total Debt	0	-	0.79
Net Cash (Debt)	141.86	53.08	15.51
Net Cash Growth	167.23%	242.26%	-
Net Cash Per Share	190.42	72.03	21.05
Filing Date Shares Outstanding	37.34	0.74	0.74
Total Common Shares Outstanding	0.75	0.74	0.74
Working Capital	143.34	50.82	14.51
Book Value Per Share	-163.87	-71.01	-31.39
Tangible Book Value	-122.86	-52.33	-23.14
Tangible Book Value Per Share	-163.87	-71.01	-31.39

Source: S&P Capital IQ. Standard template. Financial Sources.